Pharma stock jumps 3% after receiving approval for sale of durvalumab solutionPharma stock jumps 3% after receiving approval for sale of durvalumab solution

Introduction:

Pharma stock has received regulatory approval to import and distribute Durvalumab (Imfinzi) for treating unresectable hepatocellular carcinoma (uHCC) in India. This approval strengthens its oncology portfolio, expanding access to innovative cancer treatments while awaiting further statutory clearances before market launch.

Share Price movement of AstraZeneca Pharma India:

On March 3, 2025, AstraZeneca Pharma India Ltd opened at ₹6,783.00, reaching a high of ₹6,890.35 and a low of ₹6,620.10, up 3% from its previous close of ₹6,698.65. Currently, it is trading at ₹6,856.50, with a market cap of ₹17,141.25 crore.

AstraZeneca Pharma India got approval for sales:

AstraZeneca Pharma India Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and distribute Durvalumab solution for infusion (Imfinzi) in India. This approval allows its use in combination with Tremelimumab for treating patients with unresectable hepatocellular carcinoma (uHCC).  

This regulatory clearance enables AstraZeneca to market Durvalumab 120 mg/2.4 ml and 500 mg/10 ml for the newly approved indication. The company now awaits any additional statutory approvals required before launching the treatment in the Indian market.  

The announcement was initially made on February 28, 2025, under an incorrect scrip code and has now been resubmitted correctly. AstraZeneca remains committed to expanding access to innovative cancer treatments, strengthening its oncology portfolio in India.

Also Read: Penny stock hits 20% upper circuit after NCLAT sets aside insolvency proceedings

Recent news About AstraZeneca Pharma India:

AstraZeneca Pharma India has received regulatory clearance to introduce a new cancer treatment in India. This move strengthens its oncology portfolio, enhancing access to innovative therapies. The company continues to focus on expanding advanced healthcare solutions in the Indian market.

Ace investor holding of AstraZeneca Pharma India:

Shivani Tejas Trivedi holds a 2.40% stake in AstraZeneca Pharma India Ltd., with 6,00,299 shares valued at ₹411.9 crore. Her investment reflects strong confidence in the company’s growth potential, maintaining her position without any changes in the last quarter.  

Tejas Bhalchandra Trivedi has a 2.68% stake in AstraZeneca Pharma India Ltd., holding 6,69,078 shares worth ₹459.2 crore. His investment highlights a strategic long-term approach, with no change in holdings from the previous quarter, reinforcing trust in the company’s future performance.

Stock performance of AstraZeneca Pharma India  for Period of 1 week, 6 months and 1 year:

AstraZeneca Pharma India’s stock declined by 2.84% over the past week, reflecting short-term volatility. Over six months, it dipped 2.92%, indicating a stable yet cautious trend. However, the stock delivered a strong 22.9% gain over one year, showcasing long-term growth potential for investors.

Also Read: Auto stocks: How were the sales Tata motors, TVS and other auto stocks in Feb 2025?

Shareholding pattern of AstraZeneca Pharma India:

All values in %	Dec-24	Sep-24	Jun-24
Promoters	75	75	75
FII	2.92	2.9	2.79
DII	5.21	5.09	5
Retail & others	16.85	17.01	17.2

About AstraZeneca Pharma India :

AstraZeneca Pharma India is a leading pharmaceutical company specializing in innovative medicines across oncology, cardiovascular, and respiratory segments. It focuses on research-driven healthcare solutions, expanding its presence in India with advanced treatments while aligning with global healthcare advancements and regulatory approvals.

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.